Prussian Blue-Derived Nanoplatform for In Situ Amplified Photothermal/Chemodynamic/Starvation Therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Chemodynamic therapy (CDT) faces challenges in the tumor microenvironment (TME) due to low hydrogen peroxide (H2O2) and high glutathione (GSH) levels.
• CDT as a monotherapy shows limited efficacy, necessitating combination strategies for improved cancer treatment.

Purpose of the Study:

• To develop a multifunctional nanoplatform (GOx@CMPB-HN) for synergistic cancer therapy.
• To overcome TME limitations and enhance the therapeutic efficacy of CDT, photothermal therapy (PTT), and starvation therapy.

Main Methods:

• Constructed GOx@CMPB-HN nanoparticles featuring Cu-doped mesoporous Prussian blue (CMPB), glucose oxidase (GOx), and a hyaluronic acid-nitric oxide donor (HA-NO) coating.
• Utilized Cu2+ doping to enhance CDT, PTT, and starvation therapy, while GOx generated H2O2 and acidity. HA-NO coating facilitated targeted delivery and enhanced permeability and retention (EPR) effect.

Main Results:

• The nanoplatform effectively depleted GSH, generated H2O2 and acidity, and improved photothermal conversion for synergistic CDT and PTT.
• GOx@CMPB-HN nanoparticles demonstrated significant tumor growth inhibition in vitro and in vivo through targeted delivery and enhanced synergistic therapies.
• The HA-NO coating improved tumor targeting, vascular permeability, and laser penetration, leading to enhanced therapeutic outcomes.

Conclusions:

• The developed GOx@CMPB-HN nanoplatform offers a promising strategy for synergistic cancer treatment by leveraging TME properties.
• This nanoplatform presents a novel approach for cancer therapy, opening new research avenues in tumor treatment.